NCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
Academic and Community Cancer Research United
Martin-Luther-Universität Halle-Wittenberg
University of Virginia
Shandong Cancer Hospital and Institute
Muscular Dystrophy Association